866-484-8870
|
Expand search form
Menu

Innovation in Next Generation Sequencing

Making Genomics Available and Affordable for Everyone

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib: development and validation of a four-factor prognostic model. You can read the article here (subscription required). Abstract: PURPOSE Randomized trials established the superiority of ibrutinib-based […]

Read More

Utilize the first AI software for diagnosing DLBCL

Utilize the first AI software for diagnosing DLBCL

GTC is the first and only diagnostic lab to deploy true artificial intelligence (AI) software for classifications of lymphoma. Do not accept partial results, send your lymphoma to GTC for comprehensive classification using RNA/DNA and artificial intelligence. Get results in 7 days for DNA and 10 days for RNA GTC was recently published in Blood […]

Read More

Hackensack Meridian Health Partners with GTC to Establish a Reference Laboratory Offering State-of-the-Art Genomic Precision Testing

Hackensack Meridian Health Partners with Genomic Testing Cooperative to Establish a Reference Laboratory Offering State-of-the-Art Genomic Precision Testing

IRVINE, Calif. and EDISON, N.J., July 22, 2020 /PRNewswire/ — Hackensack Meridian Health (HMH) in Edison, New Jersey, and Genomic Testing Cooperative (GTC), Irvine, California, announced today an agreement to establish a next generation sequencing reference laboratory for molecular profiling. The state-of-the-art laboratory, located at JFK Medical Center in Edison, New Jersey, will use artificial intelligence […]

Read More

John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing

John Theurer Cancer Center and GTC

John Theurer Cancer Center to Establish Next Generation Sequencing Laboratory for Precision Genomic Profiling of Cancers, Adapting Testing Developed for DNA and RNA IRVINE, Calif. and Hackensack, NJ, [May 27th, 2020] John Theurer Cancer Center (JTCC), at Hackensack Meridian Health Hackensack University Medical Center in New Jersey, and Genomic Testing Cooperative (GTC), Irvine, CA, announced […]

Read More

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal cancers. * 3. Bimodal ntrk […]

Read More

New Collaboration to Offer Liquid Biopsy Testing

Genomic Testing Cooperative New Collaboration to Offer Liquid Biopsy Testing

Genomic Testing Cooperative (GTC) and C2i Genomics Announce Collaboration to Offer Liquid Biopsy Testing for Staging and Monitoring Solid Tumors Based on Pattern Recognition of Whole Genome DNA Signature IRVINE, Calif. and NEW YORK, Jan. 14, 2020 /PRNewswire/ — Genomic Testing Cooperative, LCA (GTC), a cooperative (Co-Op) company offering comprehensive genomic profiling of hematologic and […]

Read More

Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) Test

Genomic Testing Cooperative Receives Medicare Coverage for GTC-Solid Tumor Profile (434 gene) Test

GTC Solid Tumor Profile™ with 434 genes test is now covered by Medicare for patients with a wide range of solid tumor cancers Irvine, California– January 7, 2020 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has established coverage for its solid tumor molecular profile. The GTC-Solid Tumor Profile […]

Read More